Anxiety, depression and fear in general are the most common emotional problems in people with cancer and it is necessary to recognize them. The patients' attitude towards the side effects of chemotherapy has changed significantly in recent years and psychological effects, rather than physiological ones, are becoming increasingly important.
I NT ROD U CT I ON
Side effects of chemotherapy can vary greatly, depending on the properties of the drug being administered (pharmaceutical form, dosage, route of administration, interactions with other drugs). The most common side effects are nausea and vomiting, alopecia, chronic fatigue, skin and subcutaneous tissue damage, while less frequent are hepatotoxicity, neurotoxicity, cardiotoxicity, nephrotoxicity and reproductive toxicity. Individual characteristics of a patient, such as liver function, kidney function, comorbidities, age, and lifestyle habits like smoking and alcoholism, are all very important for the treatment outcome (1) . The patient's attitude towards side effects of chemotherapy has changed significantly in recent years, and psychological effects (emotional, social, or effects on sexual function) rather than physiological ones, like hair loss, fatigue and malaise associated with anaemia, are becoming increasingly important to the patient (2) . Timely information provided by professional staff and integration of patients into educational programs are amongst the most important psychosocial aspects of modern oncology (3) .
Diagnosis of malignancy causes more intense emotional reactions than of any other disease. Confusion, anxiety and stress that follow the diagnosis and emotional problems such as depression or panic disorders in people with cancer can be quite serious and it is important to recognize them. An observational study published in 2009 in Australia pointed out that the prevalence of anxiety and depression was 45% and 25%, respectively, and their role was as important as that of the general physiological factors, gastrointestinal problems, problems with nutrition and general body weakness (4) . A cross-sectional study in Iran on one hundred-fifty patients with recent diagnosis of different cancers revealed that 29.3% patients had mild anxiety, 16.7% had symptomatic anxiety, yet mild and symptomatic depression were seen in 26.7% and 21.3% patients, respectively (5) .
Several questionnaires, like BAI (Beck Anxiety Inventory), HAM-A (Hamilton Anxiety Rating Scale), SAS (Zung Self-Rating Anxiety Scale), DASS (Depression Anxiety Stress Scales), HADS (Hospital Anxiety and Depression Scale) among others, have been developed in order to evaluate components of fear such as anxiety and/or depression among patients. Fear is generally defined as individual's response to a potential threat or an actual event in order to protect life, compared to anxiety, which is not related to any specific object or phenomenon (6) . Some patients will experience only certain types of fear, while others will experience the majority of them. Some questionnaires were developed to assess the level of fear of breast and colorectal cancer screening, fear of complete cancer treatment (chemo-and radiation therapy) and fear of cancer in general. To the best of our knowledge, an instrument or questionnaire that would assess the fear of chemotherapy side effects in cancer patients was yet to be developed.
The aim of this study was to develop an instrument that can assess the patients' fear of the side effects of the ongoing therapy, and then conduct a survey to test the reliability and validity of the instrument.
MATERIALS AND METHODS

New questionnaire construction
Construction of a questionnaire on fear of chemotherapy side effects has started with the review of relevant literature. Each of 22 items was constructed in the form of positive statement that should have reflected a certain element of fear. Five possible answers were offered for each statement, in the form of the Likert's scale: "not at all-never", "some of the timesometimes", "a good part of time-often", "most of time-almost always", and" all the time-always", rated from 1 ("not at all-never") to 5 ("all the time-always"). Two items were different than the others selected as a socially desirable, with offered answers YES or NO. The final version of CheSeFS was then reviewed by two internists -oncologists and a clinical pharmacist, employed at the Clinical Centre Kragujevac. Following confirmation of the validity for contention, clarity and comprehension, the final Serbian version of CheSeFS was copied and prepared for reliability testing. The final version of CheSeFS scale is shown in Appendix 1.
Population and sample
The final versions of the new questionnaire (CheSeFS), Scale of Depression, Anxiety and Stress-21 (DASS-21) and the Short Subjective Well-being Scale (SSWS), validated in Serbian language, were tested on patients waiting for chemotherapy. The survey took place in March, April and May 2016 at two state-owned Most of time-almost always. (5) All the time-always.
I am afraid of rapid weight loss.
(1) Not at all-never. (2) Some of the time-sometimes. (3) A good part of time-often. (4) Most of time-almost always. (5) All the time-always.
I am afraid of having to take antidepressant drugs.
(1) Not at all-never.
(2) Some of the time-sometimes. (3) A good part of time-often. (4) Most of time-almost always. (5) All the time-always.
I am afraid of mouth ulcers and sore throat.
I am afraid of anaemia, nausea and fatigue.
(1) Not at all-never. All the time-always.
I am afraid of permanent diarrhoea.
I am afraid of having to wait for treatment with other patients.
I am afraid of having trouble sleeping and falling asleep.
(1) Not at all-never. (2) Some of the time-sometimes. (3) A good part of time-often. Not at all-never. (2) Some of the time-sometimes. (3) A good part of time-often. (4) Most of time-almost always. (5) All the time-always.
I am afraid of lack of expert information when needed.
14. I am afraid of lasting side effects on my heart, lung, kidneys, etc.
Not at all-never. (2) Some of the time-sometimes. (3) A good part of time-often. (4) Most of time-almost always. (5) All the time-always.
health care settings in Serbia: the Clinical Centre Kragujevac, Oncology and Radiology Centre, and the Institute of Oncology and Radiology of Vojvodina in Sremska Kamenica. The inclusion criteria were literacy and age over 18. The exclusion criteria were pregnancy, lactation, cognitive disorders, mood disorders, mental retardation and incomplete patient files. The sample of patients was of consecutive nature, i.e. all oncology and haematology patients who visited hospital on the day of survey (and met inclusion and exclusion criteria) were offered the questionnaire. Basic personal and demographic data were acquired from all participants. The questionnaires were completed by the patients themselves. The study was approved by the Ethics Committee of the Clinical Centre Kragujevac, Serbia. The patients were treated with due respect and care, according to the principles stated in the Declaration of Helsinki.
Reliability testing
Reliability of the questionnaire was tested by four methods (7) . First, internal consistency was determined through calculation of Cronbach's alpha for the whole questionnaire. Second, the questionnaire was divided by split-half method in two parts with the same number of items, and Cronbach's alpha for each of the parts was calculated. Using the alphas for both parts, number of items in each part and average correlation between items in both parts of the original questionnaire, the Spearman-Brown coefficient for the questionnaire as a whole was calculated by the Spearman-Brown "prediction" formula (8) . Third, for each item the mean score and fourth, the item variances were calculated, in order to check their suitability for the measurement of the whole extent of fear.
Factorial analysis
Exploratory factorial analysis of the questionnaire was performed in order to discover principal factors. First, suitability of the questionnaire and the sample for factorial analysis was tested by KaiserMeyer-Olkin measure of sampling adequacy and by the Bartlett's test of sphericity. Then, the factors were extracted first without rotation, with a condition that eigenvalues had to be greater than 1.0, and using Screeplot (the extracted factors were above the "elbow" of the graph) (9) . Second, reference axes were rotated orthogonally, using the Varimax method, and another extraction of the factors was made, using the same criteria as for the unrotated solution (10) . Extracted factors were then named accordingly.
Validity
The content validity of the questionnaire was evaluated by an independent panel of three experienced clinicians at the Clinical Centre Kragujevac, Serbia: two internists -oncologists and a clinical pharmacist.
The construction validity was tested by two methods: 1) convergent validity testing by comparison of the CheSeFS score with the Scale of Depression, Anxiety and Stress-21 (DASS-21) score, and 2) divergent validity testing by comparison of the CheSeFS score with the score of the Short Subjective Well-being Scale (SSWS). The permission to use the Short Subjective Well-being Scale and Scale of Depression, Anxiety and Stress-21, previously validated in Serbian population, was granted by Assist. Prof. Veljko Jovanovic, psychologist, University of Novi Sad, Serbia (11, 12) . The correlations between scores on the questionnaires were calculated. All calculations were performed by SPSS statistical software, version 20.0.
RESULTS
The first version of the CheSeFS questionnaire contained 22 items, which was, after the pilot and minor adjustments, tested on the sample of 208 patients: mean age 54.87 +/-14.54 years, male/female ratio 88/120 (42.3%/57.7%), years of formal education 12.01 +/-2.858, place of residence, urban/rural = 149/59 (71.6%/28.4%), living alone/with partner = 51/157 (24.5%/75.5%). The umber of respondents with cancer diagnosed for the first time was 154 (92.3%). The number of patients receiving chemotherapy for the first time was 192 (74.0%).
Reliability testing
After testing the original questionnaire and examining the results of the correlation matrix, mean values, variance, skewness and kurtosis of response distribution for each of the items, 8 items were removed, leaving the final version of the CheSeFS questionnaire with 14 items. Cronbach's alpha of the final version with 14 items was 0.922. Mean values of responses, standard deviations, variance, skewness and kurtosis for each item are shown in Table 1 . After division of the questionnaire by the split-half method, the Spearman-Brown coefficient for the questionnaireas a whole was calculated by the Spearman-Brown "prediction" formula, with the resulting value of 0.927. Cronbach's alpha after division was 0.841 for the first part and 0.875 for the second part of the questionnaire.
Factorial analysis
Factorial analysis was performed using the principal components method. The Kaiser-MeyerOlkin measure of sampling adequacy was 0.867 and the Bartlett's test of sphericity was significant (p = 0.000). Two factors were extracted after orthogonal rotation, explaining 61.691% of variance in total. The first factor bears 4.385 eigenvalues (31,321% of variance), the second 4.252 (30,370% of variance). The rotated component matrix is shown in Table 2 . Items 6, 7, 12, 16, 17, 19, and 24 belong to the first factor, which reflects objective physiological factors (dependent on the properties of the administered drug) affecting the fear of chemotherapy side effects. Items 10, 11, 13, 20, 21, 22, and 23 belong to the factor 2, which describes patient's emotional, psychological and sociological status affecting the fear of chemotherapy side effects.
Validity
The validity of convergent criterion was tested through non-parametric correlation between the score on the CheSeFS scale and the score on the Scale of Table 3 . Multi correlation matrix (non-parametric Spearman's coefficients at significant correlation p = 0.000) for convergent and divergent validity.
DASS-A score DASS-S score DASS-D score
DASS-21 total score SSWS score
CheSeFS score 0.572 0.572 0.536 0.595 -0.038
Depression, Anxiety and Stress-21 (DASS-21). The validity of divergent criterion was tested through non-parametric correlation between scores on the CheSeFS scale and the Short Subjective Well-being Scale (SSWS) scale. Non-parametric correlation was chosen due to non-normal distribution of some of the scores. The CheSEFS was positively correlated with the DASS-21 scale (ρ = 0.595, p = 0.000) and Spearman's correlation coefficients were the same for the DASS-A (part od DASS-21 scale measuring anxiety) and DASS-S (part od DASS-21 scale measuring stress) ρ = 0.572; p = 0.000, and Spearman's correlation coefficient was ρ = 0.536; p = 0.000 for the DASS-D (part od DASS-21 scale measuring depression). The CheSeFS had negative and low correlation with SSWS scale (ρ = -0.038, p = 0.000), explaining divergent validity. Spearman's correlation coefficients are shown in the Multi correlation matrix (Table 3) . Mean score of items explained by Factor 1 correlated well with the part of DASS-21 scale that measures anxiety (ρ = 0.603, p = 0.000), while the mean score of items explained by Factor 2 correlated well with the part of DASS-21 scale that measures depression (ρ = 0.529, p = 0.000). Population of patients who live alone, correlated much better with the part of DASS-21 scale that measures depression (ρ = 0.769, p = 0.000) than those who live with a partner (ρ = 0.452, p = 0.000). Patients under 65 years of age correlated better with a DASS-21 scale in general (ρ = 0.685 , p = 0.000) than the older ones (ρ = 0.339 , p = 0.000). Comparison of mean score values for Factor 1 and Factor 2 reveals that the mean score of the first factor is higher (14.66 > 13.76).
DISCUSSION
The present study was designed to systematically develop an instrument that assesses fears of chemotherapy side effects, and also test the reliability and validity of this instrument. Final version of the CheSeFS scale with 14 items demonstrated satisfactory reliability and both divergent and convergent validity tests had good results. It is evident that the items related to the fear of nausea and vomiting and persistent allergies after chemotherapy were eliminated first, due to low values of mean, variance and correlation coefficient. This confirms the significant progress in the development and availability of supportive antiemetic therapy, although this is one of the most common side effects in cancer patients. Patients are much more likely to experience adverse reactions like nausea and vomiting compared to the period of thirty years ago (4) . The low correlation to persistent allergies indicates that less toxic pharmaceutical forms of cytostatic drugs are available to patients, even in Serbian hospitals.
The first reaction of patients encountering a malignant disease is fear of death or fear of separation from the loved ones. Individual attitudes can vary, from complete indifference to panic disorder (13) . It is essential to recognize, at the beginning of the chemotherapy application cycle, those patients with increased risk of mental instability since depression and anxiety lead to increased morbidity and mortality rates (10) . Anxiety and stress are reactions to the most common serious adverse physiological effects of cytostatic therapy, especially during the progression and recurrence of the disease. This is consistent with the fact that depressive syndrome occurs in advanced cancer patients. The population of patients who live alone has a great representation of vulnerability in general. A lower level of fear in older population is explained by the presence of associated chronic diseases in these patients and being part of an already limited popu-lation compared to the younger ones.
Factorial analysis revealed two domains: physiological component of fear of chemotherapy side effects (Factor 1) and subjective (emotional, psychological and sociological) component of fear of chemotherapy side effects (Factor 2). The comparison indicates that patients show a higher level of fear for items found in the first domain since doctors and health care professionals assert them as serious. It is necessary for patients to read and be informed about them, because adequate information reduces anxiety and stress. However, the level of fear related to the consequences of chemotherapy that patients experience emotionally is very high. It is important to have a routine patient screening for the psychological symptoms before administering the next cycle, even when the need for such action is not immediately obvious. Patients need to describe their effect to the health care professionals involved in their treatment and management. Using reliable and valid assessment tools can help patients to verbalize and clarify their symptom experience into a more objective form, which can then be measured (14) .
There are a few limitations that need to be considered in this study. It was not possible to perform retesting after 15-30 days and determine the temporal stability of the questionnaire, due to difficulties in separating and eliminating the patients who received the last cycle. The relatively short period of time was not sufficient for the adequate number of patients who come to receive chemotherapy for the first time. In some recent studies, there were significant relationships between anxiety and depression and the type of cancer and type of treatment, thus further research in this direction should be carried out, according to the chemotherapy cycles given (5) . Due to the increasing number of cancer patients, insufficient number of doctors and nurses, as well as the lack of certain drugs, long waiting lists in our country, the reliability of this questionnaire should be examined in other countries, with the higher level of healthcare services. Health care professionals need to receive initial training and supervision in all stages of the screening procedure, so the cost-effectiveness of screening and support interventions need to be examined in future studies (15) .
CONCLUSION
Fear can be a major impediment to the applica-tion of necessary healthcare measures, and it is important that reliable and valid assessment tools are available to measure its cause and extent. Chemotherapy Side Effects Fear Scale (CheSeFS) is a reliable and valid, clinically useful tool that measures the level of patients' fear of the chemotherapy side effects. The results of this study have further implications. Psychosocial screening with feedback and information of available services should be provided by healthcare professionals in routine oncology care. Identified patients must be provided with adequate psychotherapy and expert consultations in order to be successfully treated during the therapy. Special attention should be paid to the patients under 65 years of age, as well as the group of patients living alone, without the support of a life partner or family. After this first step, a lot of comprehensive effort is needed to increase the quality of life in cancer patients.
DISCLOSURE
The authors declare that no competing financial interests or conflict of interests exist. The funders had no role in the study design, data collection and analysis, and the decision to publish the paper.
